Please login to the form below

lebrikizumab

This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

The Dermira deal saw Lilly gain both a marketed drug – medicated cloth Qbrexza (glycopyrronium) for uncontrolled excessive underarm sweating – as well as pipeline candidate lebrikizumab for atopic dermatitis, which is currently

Latest news

Lilly expands dermatology portfolio with $1.1bn Dermira deal

The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Roche had been developing lebrikizumab as a potential treatment for
Almirall eyes $62m takeover of multicytokine specialist Bioniz

The option deal comes amid an expansionist phase for Almirall, which exercised an option to buy Dermira’s anti-IL-13 antibody lebrikizumab – heading for phase 3 testing in atopic dermatitis
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

There are a number of drugs coming through the collective industry pipeline as well, including IL-13 inhibitors from Dermira (lebrikizumab) and Leo Pharma (tralokinumab) and oral JAK inhibitors such as
Dermira craters as acne drug fails late-stage test

Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully
Setback for AZ as tralokinumab flunks asthma trial

The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Pharma deals during August 2014

This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Senior Account Manager: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Lead Copywriter: Competitive

Medical Editor: Competitive

Healthcare Account Director: Competitive

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Commercial Finance Director, Healthcare Marketing Communications...: up to £90K

PMHub

Add my company

Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Mistrust in medical research: a patient perspective: The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease: Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients: We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...